The biorepository will enable researchers at the hospital to access tissue samples from across the institution. Rush and Tempus will also work together to develop 3-D organoids to test how patients may respond to specific cancer treatments.
“The collaboration we are announcing today should allow us over a very short period of time to collect thousands of bio-specimens that will be used to fuel decades of groundbreaking research,” said Dr. Ranga Krishnan, senior vice president of Rush.
The agreement builds on Rush and Tempus’ existing collaboration, under which Tempus provides the hospital with molecular sequencing and analysis for cancer patients.
More articles on health IT:
Allscripts partners with Conversa for clinical conversation platform
Congressional App Challenge names director
Kalorama: Physician frustration drives regular EMR vendor switching
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
